液態生物檢體生物標記市場－策略分析與預測（2026-2035）

預計液態生物檢體生物標記市場規模將從 2026 年的 93.3 億美元成長到 2035 年的 258.1 億美元，複合年成長率為 12.0%。

液態生物檢體生物標記市場正經歷著重大變革，其驅動力包括精準腫瘤學模式轉移、對微創診斷日益成長的需求以及循環分子特徵臨床效用的不斷擴大。這一市場演變的特點在於，人們認知到循環腫瘤DNA、循環性腫瘤細胞、遊離DNA和遊離RNA等液態生物檢體生物標記物能夠透過重複檢體採集實現全面的基因組分析，並允許對多種癌症類型進行時間序列分子監測。先進定序技術、數位PCR和人工智慧的融合，使得檢測極低頻基因組突變成為可能，同時提高了檢測的敏感度和特異性。隨著精準腫瘤學越來越依賴基因生物標記來識別可治療的突變、抗藥性機制以及不斷演變的腫瘤的異質性，醫療系統正在將液態生物檢體檢測與傳統病理學相結合，整合到多學科癌症治療中。製藥公司正在將液態生物檢體生物標記納入臨床試驗，因為基於生物標記的患者篩選能夠提高受試者招募效率，同時增加在基因明確的人群中驗證治療效果的可能性。隨著市場對多種癌症早期檢測、微量殘存疾病監測以及伴隨診斷的大量投資，液態生物檢體生物標記正逐漸成為精準腫瘤學和癌症長期管理的重要組成部分。

市場促進因素

• 精準腫瘤學的擴展是液態生物檢體標記市場的主要驅動力。精準腫瘤學依賴分子生物標記，根據腫瘤特異性基因組突變為患者匹配合適的標靶治療。隨著腫瘤治療流程中越來越需要治療前透過生物標記進行確認，對液體活體組織切片生物標記的需求也在不斷成長。由於許多臨床環境中組織樣本的取得仍然有限，對微創生物標記檢測的依賴性日益增強。診斷開發商正在擴展高靈敏度檢測方法，以實現在整個治療過程中重複的基因組評估。這種轉變增強了臨床實踐和藥物研發中對液態生物檢體生物標記的長期需求，並推動了液態生物檢體生物標記應用的持續成長。微量殘存疾病（MRD）監測因其不斷擴大的臨床效用而進一步加速了市場成長。 MRD評估能夠識別傳統影像學無法偵測到的殘留惡性細胞。在臨床實踐中，在影像學觀察出現之前，透過分子層面識別復發已成為日益成長的趨勢，因為早期干預可以改善治療方案。在臨床證據支持的情況下，醫療專業人員正在將基於循環腫瘤DNA（ctDNA）的監測納入治療後後續觀察方案。診斷公司不斷檢驗能夠檢測極低突變等位基因頻率的高靈敏度檢測方法。這項發展正在擴大生物標記的應用範圍，使其從初始診斷延伸至長期患者管理。伴隨診斷的商業性需求持續成長，這得益於製藥公司和診斷公司之間的合作。標靶癌症療法越來越需要檢驗的伴隨診斷來識別合格的患者。由於基因篩選的患者群體顯示出更高的治療反應率，製藥公司正在將生物標記檢測納入臨床開發的各個階段。監管機構正在持續評估將診斷和治療核准聯繫起來的聯合開發策略。診斷製造商正在加強與製藥公司的合作，以加速商業化。次世代定序不斷提升分析能力，並拓展臨床應用範圍。定序技術能夠利用有限的循環核酸進行全面的基因組分析。

市場限制因素

• 檢查室間分析標準標準化程度不足，導致臨床解讀持續差異，且不同平台間結果的可比較性較差。缺乏統一的方案降低了臨床可靠性和可比性。由於許多新興生物標記應用領域仍需更有力的證據來證明其長期臨床效用，因此各醫療系統的保險報銷政策並不一致。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。早期癌症通常只釋放低濃度的循環癌基因，從而降低了某些患者群體中生物標記的敏感性。循環生物標記的生物學限制給早期檢測帶來了挑戰。不同司法管轄區的監管複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

對技術和生物標記類型的深入了解

• 技術發展趨勢的特點是整合多組學體學、人工智慧驅動的分析以及高靈敏度檢測方法的重要性日益凸顯。循環腫瘤DNA (ctDNA) 是生物標記領域的領先組成部分，因為它可以透過微創血液採集提供腫瘤特異性基因組資訊。隨著腫瘤科醫師在治療方案選擇和疾病後續觀察過程中需要反覆進行分子譜分析，臨床需求不斷成長。由於早期疾病中釋放到血液中的循環DNA量有限，因此檢測靈敏度仍然是重要的阻礙因素。診斷技術開發人員正在改進定序化學過程和生物資訊流程，以檢測越來越低的突變等位基因頻率。次世代定序(NGS) 能夠從少量循環核酸中實現全面的基因組分析。在需要快速獲得結果的情況下，聚合酶鍊式反應 (PCR) 在特定突變的檢測中仍然發揮著至關重要的作用。免疫免疫檢測繼續支持特定蛋白質生物標記的檢測。分析表明，血液仍然是主要的檢體類型，因為血液採集程序可以輕鬆整合到常規臨床工作流程中，並且可以進行重複的時間序列評估。醫療專業人員正在尋求替代侵入性組織切片檢查的方法，尤其是在臨床上需要重複取樣的情況下，這種需求正在不斷成長。微小殘留病灶（MRD）監測是發展最快的臨床應用之一，因為人們經常能觀察到常規影像學檢查無法檢測到的殘留癌細胞。隨著越來越多的臨床醫生尋求在手術或全身性治療後儘早獲得分子層面的複發證據，對MRD監測的需求也在不斷成長。肺癌、乳癌、大腸癌和攝護腺癌是主要的應用領域。診斷檢查室是主要的終端用戶，醫院和學術研究機構也不斷擴展其檢測能力。人工智慧的整合變得越來越重要，因為人工智慧可以輔助對日益複雜的生物標記資料集進行突變分類、模式識別和預測建模。

競爭格局與策略展望

• 在競爭激烈的市場格局中，除了成熟的診斷和生命科學公司外，一些專注於液態生物檢體和精準腫瘤學的公司也加入了競爭。 Guardant Health憑藉其對基於血液的精準腫瘤診斷的專注以及在ctDNA技術領域的領先地位脫穎而出，構建了一個全面的產品組合，支持全面的基因組分析、治療選擇、復發監測和癌症篩檢。 Natera透過其個人化的微量殘存疾病（MRD）平台實現了策略差異化，該平台採用基於個體腫瘤資訊而非固定基因組組合的檢測方法，從而能夠對術後和全身治療後的殘留病灶進行高靈敏度監測。 Exact Sciences透過建立整合分子診斷、癌症篩檢和精準腫瘤學的腫瘤產品組合來脫穎而出，在整個疾病管理過程中擴展了基因組檢測能力，並強調早期癌症檢測。羅氏透過將藥物開發與全球最大的體外診斷業務之一相結合，保持了獨特的戰略地位，從而能夠同時開發標靶治療和伴隨診斷產品。 QIAGEN憑藉其涵蓋樣本製備、檢測開發、定序技術和生物資訊解決方案的廣泛分子診斷產品組合脫穎而出。 NeoGenomics則透過整合分子診斷、病理學、細胞遺傳學和基因組分析的綜合腫瘤檢測服務確立了其競爭優勢。兩家公司都在透過在ctDNA檢測、微小殘留疾病（MRD）平台和多癌種早期檢測方面的創新來擴展產品系列。由於需要開發伴隨診斷來配合標靶治療，診斷製造商和製藥公司之間的策略合作夥伴關係正在增加。近期一項重大進展是Volition宣布其「Capture-Seq」液態生物檢體工作流程能夠產生純度超過99%的癌症來源血漿DNA序列集，旨在提高癌症檢測的訊號品質。紀念斯隆-凱特琳癌症中心也重點介紹了液態生物檢體方法。區域業務擴張仍然是關鍵的策略重點，各公司正將目光投向快速成長的亞太地區和醫療基礎設施不斷完善的新興市場。

簡明結論

• 液態生物檢體生物標記市場預計將持續成長，這主要得益於精準腫瘤學的進步、技術創新以及臨床應用的持續拓展。從間歇性組織檢查到連續性分子評估的轉變，標誌著癌症治療的根本性變革。儘管標準化、保險報銷和靈敏度等方面仍存在挑戰，但對技術、合作關係和實證醫學的策略性投資正為市場領導帶來持續的競爭優勢。長期市場前景依然樂觀，液態生物檢體生物標記正逐步發展成為精準腫瘤學的基礎要素，在全球醫療系統中支持早期檢測、治療選擇、治療監測和復發監測。

本報告的主要益處：

• 深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
• 競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
• 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
• 實用建議：我們支援制定策略決策，以開發新的收入來源。
• 適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

• 歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
• 成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
• 競爭對手定位、策略和市場佔有率分析
• 營收成長率及預測分析：依業務板塊及地區（國家）分類
• 企業概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章：執行摘要

• 市場概述
• 主要分析結果
• 分析師意見
• 策略建議

第2章 分析方法

• 分析設計
• 資料收集和分析方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章：全球液態生物檢體生物標記市場：概述、市場規模和預測

• 市場定義和範圍
• 行業概覽
• 產業變化
• 主要市場趨勢
• 實際成果值市場規模分析
• 市場預測
• 生物標記概述
• 癌症負擔和液態生物檢體生物標記的臨床需求
• 生物標記發現與檢驗的趨勢
• 在整個患者照護過程中具有臨床效用
• 伴隨診斷與精準腫瘤學的整合
• 測試數量分析
• 患者人口統計分析及生物標記應用現況。

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 新型生物標記技術
• 產品創新
• 臨床試驗分析
• 管道分析
• 多體學整合在液態生物檢體生物標記開發的應用
• 人工智慧與生物資訊學的融合
• 技術藍圖

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章 全球液態生物檢體生物標記市場：展望分析

• 分析：依生物標記類型
• 分析：依檢體類型
• 分析：按技術平台
• 分析：透過臨床應用
• 分析：按癌症類型分類
• 分析：依測試目的

第9章 全球液態生物檢體生物標記市場：細分市場分析

• 依生物標誌類型
  • 循環腫瘤DNA（ctDNA）
  • 循環性腫瘤細胞（CTCs）
  • 無細胞DNA（cfDNA）
  • 無細胞RNA（cfRNA）
  • 其他生物標記
• 依檢體類型
  • 血
  • 尿
  • 腦脊髓液（CSF）
  • 唾液
  • 其他體液
• 透過技術平台
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫測量
  • 其他分子技術
• 臨床應用
  • 癌症的早期發現和篩檢
  • 伴隨診斷
  • 治療反應監測
  • 微量殘存疾病（MRD）監測
  • 疾病復發監測與預後評估
• 按癌症類型
  • 肺癌
  • 乳癌
  • 結腸癌
  • 攝護腺癌
  • 卵巢癌
  • 胰臟癌
  • 肝癌
  • 其他癌症
• 最終用戶
  • 醫院
  • 診斷檢查室
  • 學術研究機構
  • 其他

第10章 全球液態生物檢體生物標記市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章 全球液態生物檢體生物標記市場：國家分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 荷蘭
• 日本
• 中國
• 韓國
• 印度
• 澳洲
• 巴西
• 沙烏地阿拉伯

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 企業合併、商業夥伴關係和合作
• 新產品發布

第13章：公司簡介

• Guardant Health, Inc.
• Natera, Inc.
• Exact Sciences Corporation
• Illumina, Inc.
• QIAGEN NV
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• NeoGenomics, Inc.
• Exact Sciences Corporation
• Myriad Genetics, Inc.

第14章 全球液態生物檢體生物標記市場：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Liquid Biopsy Biomarkers Market is expected to grow at a CAGR of 12.0% from a market value of USD 9.33 billion in 2026 to USD 25.81 billion in 2035.

The liquid biopsy biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision oncology, the growing demand for minimally invasive diagnostic approaches, and the expanding clinical utility of circulating molecular signatures. The market's evolution is characterized by the recognition that liquid biopsy biomarkers, including circulating tumor DNA, circulating tumor cells, cell-free DNA, and cell-free RNA, enable comprehensive genomic profiling through repeated sample collection, making longitudinal molecular monitoring feasible across multiple cancer types. The convergence of advanced sequencing technologies, digital PCR, and artificial intelligence is enabling detection of extremely low-frequency genomic alterations with increasing sensitivity and specificity. Healthcare systems are integrating liquid biopsy testing into multidisciplinary cancer care alongside conventional pathology as precision oncology increasingly depends on genomic biomarkers that identify actionable mutations, resistance mechanisms, and evolving tumor heterogeneity. Pharmaceutical companies are incorporating liquid biopsy biomarkers into clinical trials because biomarker-guided patient selection improves enrollment efficiency while increasing the probability of demonstrating therapeutic benefit in genetically defined populations. The market is witnessing significant investment in multi-cancer early detection, minimal residual disease monitoring, and companion diagnostic development, positioning liquid biopsy biomarkers as a critical component of precision oncology and longitudinal cancer management.

Market Drivers

• The expansion of precision oncology represents the primary driver for the liquid biopsy biomarkers market. Precision oncology relies on molecular biomarkers to match patients with targeted therapies based on tumor-specific genomic alterations. Demand is increasing because oncology treatment algorithms increasingly require biomarker confirmation before therapy initiation. Tissue availability remains limited in many clinical settings, creating dependence on minimally invasive biomarker testing. Diagnostic developers are expanding high-sensitivity assays that support repeated genomic assessment throughout treatment. This transition strengthens long-term demand for liquid biopsy biomarkers across both clinical practice and pharmaceutical development, resulting in sustained growth in liquid biopsy biomarker utilization. Minimal residual disease monitoring is further accelerating market growth through expanded clinical utility. MRD assessment identifies residual malignant cells that remain undetectable using conventional imaging. Clinical practice increasingly recognizes molecular recurrence before radiographic evidence emerges because earlier intervention may improve treatment planning. Healthcare providers are incorporating ctDNA-based monitoring into post-treatment surveillance protocols where clinical evidence supports implementation. Diagnostic companies continue validating highly sensitive assays capable of detecting extremely low variant allele frequencies. This evolution broadens biomarker utilization beyond initial diagnosis into long-term patient management. Companion diagnostics continue strengthening commercial demand through pharmaceutical-diagnostic collaboration. Targeted oncology drugs increasingly require validated companion diagnostics to identify eligible patients. Pharmaceutical companies are integrating biomarker testing throughout clinical development because genetically selected populations improve therapeutic response rates. Regulatory authorities continue evaluating co-development strategies that align diagnostic approval with therapeutic authorization. Diagnostic manufacturers are strengthening collaborations with pharmaceutical sponsors to accelerate commercialization. Next-generation sequencing continues improving analytical performance and expanding clinical applications. Sequencing technologies enable comprehensive genomic profiling from limited circulating nucleic acids.

Market Restraints

• Limited analytical standardization across laboratories continues creating variability in clinical interpretation and cross-platform result comparability. The lack of harmonized protocols reduces clinical confidence and comparability. Reimbursement remains inconsistent across healthcare systems because many emerging biomarker applications still require stronger evidence demonstrating long-term clinical utility. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Early-stage cancers frequently release low concentrations of circulating tumor material, reducing biomarker sensitivity in certain patient populations. The biological limitations of circulating biomarkers create challenges for early detection. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Biomarker Type Insights

• The technology landscape is characterized by the growing importance of integrated multi-omics platforms, AI-enabled interpretation, and highly sensitive detection methods. ctDNA represents the leading biomarker segment because it provides tumor-specific genomic information through minimally invasive blood sampling. Clinical demand is increasing as oncologists require repeated molecular profiling throughout treatment selection and disease monitoring. Detection sensitivity remains a critical constraint because early-stage disease releases limited circulating DNA into the bloodstream. Diagnostic developers are improving sequencing chemistry and bioinformatics pipelines to detect increasingly lower variant allele frequencies. NGS enables comprehensive genomic profiling from limited circulating nucleic acids. PCR remains important for focused mutation detection where rapid turnaround is prioritized. Immunoassays continue supporting specific protein biomarker detection. The segment analysis reveals that blood remains the dominant sample type because collection procedures integrate easily into routine clinical workflows while enabling repeated longitudinal assessment. Demand is increasing as healthcare providers seek alternatives to invasive tissue biopsy, particularly when repeated sampling becomes clinically necessary. MRD monitoring represents one of the fastest-evolving clinical applications because residual cancer cells frequently remain undetectable through conventional imaging. Demand is increasing as clinicians seek earlier molecular evidence of recurrence following surgery or systemic therapy. Lung cancer, breast cancer, colorectal cancer, and prostate cancer represent significant applications. Diagnostic laboratories represent the leading end-user segment, with hospitals and academic research institutes expanding testing capabilities. The integration of AI is becoming increasingly important because AI is supporting variant classification, pattern recognition, and predictive modeling across increasingly complex biomarker datasets.

Competitive and Strategic Outlook

• The competitive landscape features specialized liquid biopsy and precision oncology companies alongside established diagnostics and life science providers. Guardant Health distinguishes itself through its exclusive focus on blood-based precision oncology diagnostics and its leadership in ctDNA technologies, building a comprehensive portfolio supporting comprehensive genomic profiling, treatment selection, recurrence monitoring, and cancer screening. Natera has established strategic differentiation through its personalized minimal residual disease platform, leveraging individualized tumor-informed assays rather than fixed genomic panels to enable highly sensitive monitoring of residual disease following surgery and systemic treatment. Exact Sciences differentiates itself by combining molecular diagnostics, cancer screening, and precision oncology into an integrated oncology portfolio, emphasizing earlier cancer detection while expanding genomic testing capabilities across disease management pathways. Roche maintains a strategically distinct position by integrating pharmaceutical development with one of the world's largest in vitro diagnostics businesses, enabling simultaneous development of targeted therapies and companion diagnostics. QIAGEN differentiates itself through its extensive molecular diagnostics portfolio spanning sample preparation, assay development, sequencing technologies, and bioinformatics solutions. NeoGenomics has established competitive strength through comprehensive oncology laboratory services integrating molecular diagnostics, pathology, cytogenetics, and genomic profiling. Companies are pursuing product portfolio expansion through innovation in ctDNA assays, MRD platforms, and multi-cancer early detection tests. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include Volition saying its Capture-Seq liquid biopsy workflow can generate cancer-derived plasma DNA sequence sets with more than 99% purity, intended to improve signal quality in cancer detection. Memorial Sloan Kettering highlighted a liquid biopsy approach that uses AI and nanosensors to detect brain tumors and potentially distinguish among cancer types. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The liquid biopsy biomarkers market is positioned for sustained growth driven by the convergence of precision oncology, technological innovation, and expanding clinical applications. The transition from episodic tissue-based evaluation toward continuous molecular assessment represents a fundamental shift in cancer management. While challenges related to standardization, reimbursement, and sensitivity persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with liquid biopsy biomarkers evolving into a foundational component of precision oncology, supporting early detection, treatment selection, therapeutic monitoring, and recurrence surveillance across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Liquid Biopsy Biomarkers Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Biomarker Landscape Overview
• 3.8 Cancer Burden and Clinical Need for Liquid Biopsy Biomarkers
• 3.9 Biomarker Discovery and Validation Landscape
• 3.10 Clinical Utility Across the Patient Care Continuum
• 3.11 Companion Diagnostics and Precision Oncology Integration
• 3.12 Testing Volume Analysis
• 3.13 Patient Population and Biomarker Adoption Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Multi-Omics Integration in Liquid Biopsy Biomarker Development
• 6.6 Artificial Intelligence and Bioinformatics Integration
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Liquid Biopsy Biomarkers Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Sample Type
• 8.3 Analysis by Technology Platform
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Cancer Type
• 8.6 Analysis by Testing Purpose

9. Global Liquid Biopsy Biomarkers Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Circulating Tumor DNA (ctDNA)
  • 9.1.2 Circulating Tumor Cells (CTCs)
  • 9.1.3 Cell-Free DNA (cfDNA)
  • 9.1.4 Cell-Free RNA (cfRNA)
  • 9.1.5 Other Biomarkers
• 9.2 By Sample Type
  • 9.2.1 Blood
  • 9.2.2 Urine
  • 9.2.3 Cerebrospinal Fluid (CSF)
  • 9.2.4 Saliva
  • 9.2.5 Other Body Fluids
• 9.3 By Technology Platform
  • 9.3.1 Next-Generation Sequencing (NGS)
  • 9.3.2 Polymerase Chain Reaction (PCR)
  • 9.3.3 Immunoassays
  • 9.3.4 Other Molecular Technologies
• 9.4 By Clinical Application
  • 9.4.1 Early Cancer Detection & Screening
  • 9.4.2 Companion Diagnostics
  • 9.4.3 Treatment Response Monitoring
  • 9.4.4 Minimal Residual Disease (MRD) Monitoring
  • 9.4.5 Disease Recurrence Monitoring & Prognostic Assessment
• 9.5 By Cancer Type
  • 9.5.1 Lung Cancer
  • 9.5.2 Breast Cancer
  • 9.5.3 Colorectal Cancer
  • 9.5.4 Prostate Cancer
  • 9.5.5 Ovarian Cancer
  • 9.5.6 Pancreatic Cancer
  • 9.5.7 Liver Cancer
  • 9.5.8 Other Cancers
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Diagnostic Laboratories
  • 9.6.3 Academic & Research Institutes
  • 9.6.4 Others

10. Global Liquid Biopsy Biomarkers Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Liquid Biopsy Biomarkers Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 South Korea
• 11.12 India
• 11.13 Australia
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Guardant Health, Inc.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Natera, Inc.
• 13.3 Exact Sciences Corporation
• 13.4 Illumina, Inc.
• 13.5 QIAGEN N.V.
• 13.6 Bio-Rad Laboratories, Inc.
• 13.7 F. Hoffmann-La Roche Ltd.
• 13.8 NeoGenomics, Inc.
• 13.9 Exact Sciences Corporation
• 13.10 Myriad Genetics, Inc.

14. Global Liquid Biopsy Biomarkers Market Commercial Forecast Analysis

• 14.1 Commercial Forecast by Biomarker Type
• 14.2 Commercial Forecast by Technology Platform
• 14.3 Commercial Forecast by Clinical Application
• 14.4 Commercial Forecast by Cancer Type
• 14.5 Commercial Forecast by End User

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends